Cardio Diagnostics Holdings Goes Public via Business Combination with Mana Capital Acquisition Corp.
October 26, 2022
Cardio Diagnostics Holdings, Inc., a precision cardiovascular diagnostics company using epigenetics and AI, completed a business combination with special purpose acquisition company Mana Capital Acquisition Corp. The combined company began trading on the Nasdaq under the ticker symbols CDIO and CDIOW, providing Cardio with public-market access and capital to commercialize its epigenetics-based cardiovascular tests.
- Buyers
- Mana Capital Acquisition Corp.
- Targets
- Cardio Diagnostics Holdings, Inc.
- Industry
- Biotechnology
- Location
- Illinois, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
CardioOne Acquires CardioDiagnostics
April 24, 2025
Healthcare Services
CardioOne, a national growth and operational partner for independent cardiology practices, has acquired CardioDiagnostics, a provider of advanced ECG and remote patient monitoring (RPM) technologies. The deal integrates CardioDiagnostics’ cloud-based monitoring, analytics and RPM capabilities into CardioOne’s practice management platform to expand virtual care and enhance cardiology practice services.
-
Novo Nordisk Acquires Cardior Pharmaceuticals from EQT Life Sciences
March 25, 2024
Biotechnology
Novo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to EUR 1.025 billion, including an upfront payment and contingent development and commercial milestone payments. Cardior, a Hannover-based clinical-stage biotech focused on RNA-targeted therapies for cardiovascular disease, is currently majority-backed by EQT Life Sciences; the deal is expected to close in Q2 2024 subject to regulatory approvals.
-
Haemonetics Acquires Cardiva Medical
January 20, 2021
Medical Devices
Haemonetics Corporation agreed to acquire Cardiva Medical, Inc., a privately-held maker of vascular closure systems based in Santa Clara, California, for $475 million upfront and up to $35 million in contingent consideration. The acquisition expands Haemonetics' hospital portfolio and its presence in the interventional cardiology and electrophysiology markets and is expected to be accretive to revenue growth.
-
Martis Capital Invests in DCN Dx
November 19, 2020
Medical Devices
Martis Capital has made a growth equity investment in DCN Dx, a Carlsbad, California-based lateral flow diagnostics developer and contract developer of rapid point-of-care tests. As part of the transaction, Charlie Mamrak will join DCN Dx as CEO; the capital will be used to accelerate growth and expand the company's diagnostic capabilities. Financial terms were not disclosed and Pegasus Capital and TM Capital advised on the deal.
-
Ginkgo Bioworks Acquires Proof Diagnostics
February 28, 2024
Biotechnology
Ginkgo Bioworks has acquired Proof Diagnostics to integrate Proof's OMEGA nuclease libraries and portable diagnostic technologies into Ginkgo’s gene therapy and genetic medicines platform. The deal expands Ginkgo’s gene editing toolkit and diagnostic capabilities to better serve customers developing programmable medicines and rapid detection systems.
-
Wellspring Capital Management Acquires Center for Diagnostic Imaging
March 15, 2019
Healthcare Services
Wellspring Capital Management, a New York-based private equity firm, has closed the acquisition of Center for Diagnostic Imaging (CDI), a Minneapolis-headquartered provider of outpatient diagnostic imaging and interventional radiology services. Wellspring said it will partner with CDI's management to support growth initiatives, operating improvements and potential add-on acquisitions to expand CDI's national network and capabilities.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.